Enumeral Biomedical Holdings, Inc. (OTC: ENUM) is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. Enumeral’s unique platform allows the identification and characterization of promising new drugs relevant to cancer, infectious and inflammatory diseases, providing for the potential to positively affect millions of patients who are underserved by current therapeutic alternatives. The core technology behind the company’s platform was developed at and licensed from the Massachusetts Institute of Technology, Harvard University, Whitehead Institute for Biomedical Research, and Massachusetts General Hospital. For more information, visit the company’s website at www.enumeral.com